The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Ocugen has completed enrollment in liMeliGhT, its phase 3 clinical trial of OCU400 for the treatment of retinitis pigmentosa (RP). The company describes liMeliGHT as a 1-year clinical trial that will ...

March is Workplace Eye Awareness Month. The guidelines associated with eye safety in the workplace do not just apply to the general public but to eye care clinicians as well.

Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...

TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...

In this podcast, Philadelphia cornea and glaucoma surgeon Brian Shafer, MD, discusses the procedures and processes involved ...

Host Deborah Ristvedt, DO, welcomes Trattler to discuss how early inspirations, mentorship, collaboration, and a philosophy ...

The EnVision Summit—billed as the “ultimate gathering place for ophthalmic and optometric professionals”—has come to a close ...

The authors of a new study 1 emphasized the clear visual benefits that low-vision patients experience during low-vision rehabilitation. However, they cited “substantial gaps” in the research in that ...

Real-world evidence links higher injection frequency to better VA outcomes and reduced CST fluctuations, reinforcing durability as a primary unmet need in nAMD and DME management.

In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...